Blog Series: NIAID-DVI
Early genome-wide host transcriptional responses to dengue that correlate with neutralizing antibody titer following vaccination and natural infection
Stephen Popper
Stanford University School of Medicine
Vaccine development has been typically hampered because we don't have a good understanding of the correlates of protection or the links between innate and adaptive immune responses. We also have a limited understanding of the role of background immune status and it's affect on subsequent infection or vaccination. In order to identify links between early host responses and later adaptive immune responses, Popper's group studies the genome-wide transcriptional response to dengue during vaccine trial (a controlled setting) and in natural infection settings.
Stephen Popper
Stanford University School of Medicine
Vaccine development has been typically hampered because we don't have a good understanding of the correlates of protection or the links between innate and adaptive immune responses. We also have a limited understanding of the role of background immune status and it's affect on subsequent infection or vaccination. In order to identify links between early host responses and later adaptive immune responses, Popper's group studies the genome-wide transcriptional response to dengue during vaccine trial (a controlled setting) and in natural infection settings.
- They characterized the temporal dynamics of transcript abundance in subjects vaccinated with rDEN3delta30/31 (TetraVax-DV live vaccine candidate Den3 component developed by NIAID).
- Of Note:
- During early transcriptional response there is an interferon-associated transcript expression pattern that peaked in most subjects between day 6 and day 12 post-immunization and this correlated with the titer of neutralizing antibodies (PRNT60) measured at day 42.
In their newest work...
